Meeting Coverage

Meeting Coverage

Updates from major medical meetings in the field of hematology/oncology

On location

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia

In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia (HCL), three-quarters of participants responded to treatment....
On location

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...
On location

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...
On location

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib led to...
On location

Evaluating FT-2102 in IDH1-Mutated AML or MDS

According to interim data from a first-in-human phase I trial, treatment with FT-2102, a selective inhibitor of mutant IDH1, was tolerable and demonstrated anti-leukemic...
On location

Synthetic Hepcidin Options Safe in Patients With Iron Disorders, But Efficacy Data Still Preliminary

Two studies presented at the 23rd Congress of the European Hematology Association examined the safety and pharmacokinetics of two synthetic hepcidin options for the...
On location

Higher Complete Response Rates With Polatuzumab Vedotin, Bendamustine, and Rituximab Combo in DLBCL

Adding polatuzumab vedotin (an antibodydrug conjugate targeting CD79b-positive cells) to the combination of bendamustine and rituximab (BR) extended survival and increased complete responses (CRs)...
On location

Fostamatinib Increases Hemoglobin Levels in Warm Antibody Autoimmune Hemolytic Anemia

According to findings from a phase II SOAR study presented at the 23rd Congress of the European Hematology Association, twice-daily fostamatinib offered short-term improvement...
On location

Chemotherapy-Free Combination Shows Efficacy in Untreated Follicular Lymphoma

The randomized, global, phase III RELEVANCE trial showed that a regimen of lenalidomide and rituximab (R2) had similar safety and efficacy to a rituximab-based...
On location

Positive Results With Ivosidenib in Patients With High-Risk, Previously Treated AML

Treatment with ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, led to durable remissions among people with relapsed or refractory, IDH1-mutated acute myeloid leukemia...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.